Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC

In separate trials, the RET inhibitor selpercatinib showed superiority over standard of care in RET-mutated medullary thyroid cancer and in RET fusion–positive non–small cell lung cancer—although researchers say more follow-up is needed. The findings highlight the importance of tumor sequencing.